Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Other Non-Current Liabilities (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Other Non-Current Liabilities for 12 consecutive years, with $2.5 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Other Non-Current Liabilities rose 63.27% year-over-year to $2.5 million, compared with a TTM value of $2.5 million through Dec 2024, up 63.27%, and an annual FY2024 reading of $2.5 million, up 63.27% over the prior year.
  • Other Non-Current Liabilities was $2.5 million for Q4 2024 at BioRestorative Therapies, down from $3.5 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $14.7 million in Q2 2020 and bottomed at $1.2 million in Q1 2020.
  • Average Other Non-Current Liabilities over 5 years is $5.8 million, with a median of $3.5 million recorded in 2024.
  • The sharpest move saw Other Non-Current Liabilities soared 102374.73% in 2020, then plummeted 72.14% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $2.5 million in 2020, then surged by 337.2% to $10.8 million in 2021, then plummeted by 48.76% to $5.5 million in 2022, then tumbled by 72.14% to $1.5 million in 2023, then skyrocketed by 63.27% to $2.5 million in 2024.
  • Business Quant data shows Other Non-Current Liabilities for BRTX at $2.5 million in Q4 2024, $3.5 million in Q3 2024, and $4.5 million in Q2 2024.